Drug development and safety evaluation of epigenetic drugs

Abstract

For safety assessment of epigenetic drugs, indirect effects associated with changes in gene expression should be considered in addition to the direct effects of DNA methylation, demethylation and histone-modification. For example, the impact on the next generation and the long-term effects such as carcinogenicity would be pointed out.

In this presentation, we refer to the toxicities and adverse effects of the epigenetic drugs that have been approved in nonclinical and clinical studies and introduce the points to consider for future development of epigenetic drugs.